Malhotra, Usha
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers on CoChatORCID 0009-0003-3184-9605
Most cited papers
- Verified
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet
Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments
Cited by 1,169
- Verified
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 394
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free